SV2002000036A - Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11111/rm/ma - Google Patents

Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11111/rm/ma

Info

Publication number
SV2002000036A
SV2002000036A SV2000000036A SV2000000036A SV2002000036A SV 2002000036 A SV2002000036 A SV 2002000036A SV 2000000036 A SV2000000036 A SV 2000000036A SV 2000000036 A SV2000000036 A SV 2000000036A SV 2002000036 A SV2002000036 A SV 2002000036A
Authority
SV
El Salvador
Prior art keywords
hmg
dihydroxyl
reductase
ref
salts
Prior art date
Application number
SV2000000036A
Other languages
English (en)
Inventor
Edward J J Grabowski
Richard D Tillyer
Paul J Reider
Jose M Vega
Feng Xu
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of SV2002000036A publication Critical patent/SV2002000036A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

EL PRESENTE INVENTO OFRECE METODOS Y COMPOSICIONES FARMACEUTICAS PARA LA INHIBICION DE REDUCTASA HMG-CoA, ASI COMO EL TRATAMIENTO Y/O REDUCCION DEL RIESGO DE ENFERMEDADES Y CONDICIONES QUE AFECTAN LA INHIBICION DE REDUCTASA HMG-CoA, QUE COMPRENDE LA ADMINISTRACION ORAL DE UNA CANTIDAD EFECTIVA TERAPEUTICAMENTE DE UN COMPUESTO SELECCIONADO DE UNA ESTATINA DE ACIDO ABIERTO DE DIHIDROXILO Y UNA SAL O ESTER CORRESPONDIENTE FARMACEUTICAMENTE ACEPTABLE EN FORMA DE DOSIS FARMACEUTICA DE LIBERACION RETRASADA A UN PACIENTE QUE NECESITE DICHO TRATAMIENTO, DONDE UNA IMPORTANTE LIBERACION DEL COMPUESTO DE LA DOSIS SE RETRASA HASTA QUE LA DOSIS PASE AL ESTOMAGO.
SV2000000036A 1999-03-08 2000-03-08 Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11111/rm/ma SV2002000036A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12322799P 1999-03-08 1999-03-08
US26474499A 1999-03-09 1999-03-09
PCT/US2000/002626 WO2000053173A1 (en) 1999-03-08 2000-02-02 Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors

Publications (1)

Publication Number Publication Date
SV2002000036A true SV2002000036A (es) 2002-02-05

Family

ID=26821357

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2000000036A SV2002000036A (es) 1999-03-08 2000-03-08 Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11111/rm/ma

Country Status (9)

Country Link
EP (1) EP1161236A1 (es)
JP (2) JP2002538202A (es)
AR (1) AR022856A1 (es)
AU (1) AU2866400A (es)
CA (1) CA2364253A1 (es)
CO (1) CO5150193A1 (es)
PE (1) PE20001559A1 (es)
SV (1) SV2002000036A (es)
WO (1) WO2000053173A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523948A (ja) * 1999-11-04 2003-08-12 アンドルクス コーポレーション アミロイドβ前駆体障害の治療法
AU2001288724A1 (en) * 2000-09-06 2002-03-22 Merck & Co., Inc. Dihydroxy open-acid salt of simvastatin
SK4112003A3 (en) * 2000-10-12 2004-01-08 Nissan Chemical Ind Ltd Preventives and remedies for complications of diabetes
IL160077A0 (en) * 2001-08-16 2004-06-20 Teva Pharma Processes for preparing calcium salt forms of statins
KR20040026705A (ko) 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
CN1612747A (zh) * 2002-01-09 2005-05-04 克鲁塞尔荷兰公司 促红细胞生成素在预防或治疗心力衰竭中的用途
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
ATE428411T1 (de) * 2003-11-07 2009-05-15 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
US10208351B2 (en) 2013-10-18 2019-02-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) RNY-derived small RNAs as biomarkers for atherosclerosis-related disorders
KR20190142406A (ko) * 2017-05-15 2019-12-26 유니버시티 오브 신시내티 심바스타틴의 하나 이상의 대사 산물들을 직접 투여함으로써 무혈관성 연골 조직의 결함들을 치료하기 위한 조성물들 및 방법들
CN113134086B (zh) * 2020-01-20 2024-05-24 深圳市长卿医学研究院 一种降血脂的药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
PL186907B1 (pl) * 1995-12-22 2004-03-31 Kowa Co Kompozycja farmaceutyczna stabilizowana czynnikiem zasadowym
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor

Also Published As

Publication number Publication date
CO5150193A1 (es) 2002-04-29
AU2866400A (en) 2000-09-28
PE20001559A1 (es) 2001-01-16
AR022856A1 (es) 2002-09-04
EP1161236A1 (en) 2001-12-12
CA2364253A1 (en) 2000-09-14
JP2002538202A (ja) 2002-11-12
WO2000053173A1 (en) 2000-09-14
JP2000256191A (ja) 2000-09-19

Similar Documents

Publication Publication Date Title
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
SV2002000035A (es) Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11121/rm/ta
SV2002000036A (es) Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11111/rm/ma
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
HK1057899A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
NZ514574A (en) Novel method of treatment
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
HK1087702A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
MXPA04009352A (es) Terapia de combinacion para el tratamiento de la enfermedad de parkinson con inhibidores de ciclooxigenasa-2 (cox2).
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2007126964A3 (en) Kinase inhibitors
WO2005016326A3 (en) Analogs of thalidomide as potential angiogenesis inhibitors
WO2003065982A3 (en) Engineering absorption of therapeutic compounds via colonic transporters
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
RU2008103617A (ru) Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
UA89035C2 (ru) Эфиры гидроксамовых кислот и их фармацевтическое применение
ECSP066878A (es) [hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa
CY1106763T1 (el) Προληπτικα ή θεραπευτικα μεσα για φλεγμονωδεις νοσους του εντερου
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
IL300151A (en) Combinations for cancer treatment
SI1750703T1 (sl) Postopek za zmanjšanje gastrointestinalne toksičnosti zaradi dajanja tegafurja
ATE268174T1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
PT1150704E (pt) Melagatran para o tratamento da inflamacao
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
AR039162A1 (es) Formulaciones de venlafaxina de liberacion extendida